Clorox’s latest quarter was met with a negative market reaction, as management acknowledged a slower-than-expected pace of improvement in several business areas. CEO Linda Rendle cited the completion of a major enterprise resource planning (ERP) system rollout as a foundational step, but noted that supply chain costs were higher and margin improvement was gradual. The cleaning and international segments performed well, but momentum lagged in the Litter and Food divisions. Rendle characterized this as a "mixed" period, highlighting that although some categories gained market share, others struggled with competitive pressures and category declines.

Is now the time to buy CLX? Find out in our full research report (it’s free for active Edge members).

While we enjoy listening to the management's commentary, our favorite part of earnings calls are the analyst questions. Those are unscripted and can often highlight topics that management teams would rather avoid or topics where the answer is complicated. Here is what has caught our attention.

Our Top 5 Analyst Questions From Clorox’s Q1 Earnings Call

• Peter Grom (UBS Financial) asked why improvement in certain categories lagged expectations and about cost inflation into next year. CEO Linda Rendle cited slower progress in Litter and Food, while CFO Luc Bellet noted cost volatility and mitigation planning.
• Filippo Falorni (Citigroup) pressed for detail on shelf space gains and cost-saving strategies. Rendle said distribution points were up 5%, but shelf placement work remains. Bellet outlined a mix of revenue growth management, productivity, and reformulation levers.
• Andrea Teixeira (JPMorgan) inquired about category contraction and revenue growth management (RGM) levers. Rendle emphasized resilient consumer demand for branded products and ongoing RGM initiatives, including targeted price adjustments in test markets.
• Olivia Tong Cheang (Raymond James) sought clarity on balancing growth and profitability in Glad, given resin costs. Rendle said value superiority and ongoing investment in innovation and brand support remain top priorities, with price changes considered as needed.
• Lauren Lieberman (Barclays) asked about the timeline and cost impact of ERP stabilization. Rendle and Bellet described incremental logistics and fulfillment costs that are now declining, with service levels returning to normal and cost savings expected to ramp up.

Catalysts in Upcoming Quarters

In the quarters ahead, our analysts will be focused on (1) the pace at which Clorox translates shelf space gains and new product launches into stronger sales and market share, (2) the company’s execution on cost mitigation and ability to absorb input cost inflation, and (3) progress on GOJO integration and realization of anticipated synergies. Any change in consumer behavior or further cost volatility will also be important markers.

Clorox currently trades at $90.03, down from $96.44 just before the earnings. Is the company at an inflection point that warrants a buy or sell? See for yourself in our full research report (it’s free).

Our Favorite Stocks Right Now

ONE MORE THING: Top 5 Growth Stocks. The biggest stock winners almost always had one thing in common before they ran. Revenue growing like crazy. Meta. CrowdStrike. Broadcom. Our AI flagged all three. They returned 315%, 314%, and 455%, respectively.

Find out which 5 stocks it's flagging for this month - FREE. Get Our Top 5 Growth Stocks for Free HERE.

Stocks that have made our list include now familiar names such as Nvidia (+1,326% between June 2020 and June 2025) as well as under-the-radar businesses like the once-small-cap company Exlservice (+354% five-year return). Find your next big winner with StockStory today.